AbbVie’s (ABBV) decision to exercise an exclusive option to license Argenx’s (ARGX) anti-GARP antibody, ARGX-115, suggests positive preclinical data, Piper Jaffray analyst Edward Tenthoff tells investors in a research note. The analyst looks for investigational new drug application filing plans this year. He reiterates an Overweight rating on shares of Argenx with a $130 price target.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.